Summary
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Dutch generics market had total revenues of $1.1bn in 2018, representing a compound annual growth rate (CAGR) of 2.1% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2% between 2014 and 2018, to reach 77.2% of total pharma volume.
- The Dutch government is actively stopping companies raising pharmaceutical prices in conjunction with the Belgian government, which is slowing generics market growth, as well as in the wider pharmaceutical industry.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the Netherlands
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts by both value and volume
Reasons to buy
- What was the size of the Netherlands generics market by value in 2018?
- What will be the size of the Netherlands generics market in 2023?
- What factors are affecting the strength of competition in the Netherlands generics market?
- How has the market performed over the last five years?
- How large is the Netherlands’s generics market in relation to its regional counterparts?
'
Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. Which players have been most successful in the recent past (1-3 years)?
7.3. What mergers or acquisitions have taken place in the last year?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.
8.4. Sanofi SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Netherlands generics market value: $ million, 2014-18
Table 2: Netherlands generics market volume: % of total pharma, 2014-18
Table 3: Netherlands generics market geography segmentation: $ million, 2018
Table 4: Netherlands generics market value forecast: $ million, 2018-23
Table 5: Netherlands generics market volume forecast: % of total pharma, 2018-23
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: Sanofi SA: key facts
Table 17: Sanofi SA: Annual Financial Ratios
Table 18: Sanofi SA: Key Employees
Table 19: Sanofi SA: Key Employees Continued
Table 20: Netherlands size of population (million), 2014-18
Table 21: Netherlands gdp (constant 2005 prices, $ billion), 2014-18
Table 22: Netherlands gdp (current prices, $ billion), 2014-18
Table 23: Netherlands inflation, 2014-18
Table 24: Netherlands consumer price index (absolute), 2014-18
Table 25: Netherlands exchange rate, 2014-18
List of Figures
Figure 1: Netherlands generics market value: $ million, 2014-18
Figure 2: Netherlands generics market volume: % of total pharma, 2014-18
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2018
Figure 4: Netherlands generics market value forecast: $ million, 2018-23
Figure 5: Netherlands generics market volume forecast: % of total pharma, 2018-23
Figure 6: Forces driving competition in the generics market in the Netherlands, 2018
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2018
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2018
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2018
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2018
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2018
